FSDC To Keep Close Vigil On Illegal Influx Of Narcotics

Jaipur, 4 Jan 2024: The information of supplies made by Narcotic Drugs and Psychotropic Substances (NDPS) drug manufacturing companies established outside Rajasthan to the distributors of the state will be collected from drug controllers of the respective states.

If any difference is found in the quantity of supply, sale and stock, then action will be taken against all the parties concerned including the company. The stock of NDPS medicines should be limited on the lines of Uttar Pradesh and Uttarakhand.

The health department took the decision to ensure that the NDPS drugs should not be used for addiction, and it should only be used for the treatment of mental health issues.

The health department is taking necessary steps to save the young generation of the state from drug addiction and to realise the resolve of drug-free Rajasthan.

A health department official said in the meeting of the concerned departments on Tuesday, directions have been issued to strictly stop the illegal trade of narcotics and psychotropic drugs influx in the state.

The police and drug control department officials should ensure strict action against illegal sale of NDPS medicines. Effective monitoring of the sale of NDPS medicines should be done by licenced wholesale and retail drug dealers. If any seller is found selling such medicines without a licence, then action should be taken against him under the sections of NDPS Act, said a health department official.

If any licenced medicine seller is found involved in illegal NDPS drug trade, then a letter should be written to the Rajasthan Pharmacy Council to cancel the licence and registration of that shop and the pharmacist working at the shop. The social justice and empowerment department should take action against unregistered de-addiction centres.

Related Posts

AstraZeneca, NIPER Raebareli partner to upgrade 25 clinical trail sites

New Delhi: AstraZeneca’s India-arm has partnered with National Institute of Pharmaceutical Education and Research (NIPER), Raebareli, to build clinical research capabilities at 25 emerging geographies in a bid to extend…

FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash

Following a bumpy regulatory road that involved a refusal-to-file, ImmunityBio has won FDA approval to expand Anktiva into papillary-only non-muscle-invasive bladder cancer (NMIBC). Wednesday’s approval comes nearly three months ahead…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

AstraZeneca, NIPER Raebareli partner to upgrade 25 clinical trail sites

AstraZeneca, NIPER Raebareli partner to upgrade 25 clinical trail sites

FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash

FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash

Sun Pharma Approves Rs 10,000 Crore Fundraising Through NCDs

Sun Pharma Approves Rs 10,000 Crore Fundraising Through NCDs

‘Bone Bonding’ between Mothers and Children, thanks to Meticulous Bone Grafting

‘Bone Bonding’ between Mothers and Children, thanks to Meticulous Bone Grafting

Governments have moved for Price Transparency in Hospitals to help patients cope with bills

Governments have moved for Price Transparency in Hospitals to help patients cope with bills

The Most Innovative Medical Devices of 2026: Breakthrough Technologies Target Heart Disease, Cancer, Neurological Disorders and Kidney Dysfunction

The Most Innovative Medical Devices of 2026: Breakthrough Technologies Target Heart Disease, Cancer, Neurological Disorders and Kidney Dysfunction